Evidence map›Paper›PMID 42086278›Full record

ArticleDiabetes, obesity & metabolism2026

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Neda Al Rawashdh, Bimal V Patel, Sharon M Wang, Richard M Zur, Pablo Anaya, Emily B Kahn, Jordan E Pinsker, Ravid Sasson-Katchalski, Alex C Trahan, Laurel H Messer and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05785832 (A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05785832 nacompletednot on this map

A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)

TypeinterventionalSponsorTandem Diabetes Care, Inc.Ran2023 to 2024Enrolled319ConditionsType 2 Diabetes Treated With InsulinArmst:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Neda Al RawashdhIQVIA, Real-World Evidence Solutions, Falls Church, Virginia, USA.ORCID 0009-0009-6840-3360
Bimal V PatelTandem Diabetes Care, San Diego, California, USA.
Sharon M WangTandem Diabetes Care, San Diego, California, USA.
Richard M ZurIQVIA, Real-World Evidence Solutions, Falls Church, Virginia, USA.
Pablo AnayaIQVIA, Real-World Evidence Solutions, Falls Church, Virginia, USA.
Emily B KahnIQVIA, Real-World Evidence Solutions, Falls Church, Virginia, USA.
Jordan E PinskerTandem Diabetes Care, San Diego, California, USA.
Ravid Sasson-KatchalskiTandem Diabetes Care, San Diego, California, USA.
Alex C TrahanTandem Diabetes Care, San Diego, California, USA.
Laurel H MesserTandem Diabetes Care, San Diego, California, USA.ORCID 0000-0001-7493-0989
Kimia AssadiTandem Diabetes Care, San Diego, California, USA.
Yogish C KudvaDivision of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Roy W BeckJaeb Center for Health Research, Tampa, Florida, USA.

Funding

Tandem Diabetes Care
6 · The paper itself

Abstract

objectiveAutomated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. MATERIALS AND

methodsThe IQVIA CORE Diabetes Model v10.0 was employed to simulate the impact of using the t:slim X2 insulin pump with Control-IQ+ technology (Control-IQ+) versus MDI/CGM over a 50-year period using data from the 2IQP randomized controlled trial (NCT05785832). Trial data informed cohort demographics, intervention effects and resource utilization while literature sources provided health state utilities and costs. Scenario analyses examined the effect of Control-IQ+ on reducing HbA1c based on alternative HbA1c progression estimates from the Swedish National Diabetes Registry and alternative resource use and treatment effects from real-world evidence.

resultsThe base case analysis indicated that direct medical costs per individual for type 2 diabetes management with Control-IQ+ were $239 935 compared to $209 792 with MDI/CGM use. Control-IQ+ resulted in 0.51 additional quality-adjusted life years (QALYs: 10.36 vs. 9.85 for MDI/CGM), yielding an incremental cost-effectiveness ratio (ICER) of $59 417 per QALY, 95% CI: ($55 836, $62 998). In probabilistic sensitivity analyses, 89% of simulations produced ICERs below $100 000/QALY. ICERs across all scenarios remained below $100 000 per QALY.

conclusionsControl-IQ+ is associated with increased life expectancy, higher QALYs and reduced complication rates. These findings suggest that Control-IQ+ is cost-effective relative to MDI/CGM for managing patients with type 2 diabetes in the United States.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinInsulin Infusion SystemsAdultBlood GlucoseContinuous Glucose MonitoringCost-Benefit AnalysisCost-Effectiveness AnalysisFemaleGlycated HemoglobinHumansHypoglycemiaMaleMiddle AgedQuality-Adjusted Life YearsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinautomated insulin deliveryControl‐IQ+cost‐effectivenesstype 2 diabetes

Identifiers

PMID42086278
PMCPMC13243966

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.